{"id":70781,"date":"2026-05-12T11:03:24","date_gmt":"2026-05-12T11:03:24","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70781"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"hgh-fragment-176-191","status":"publish","type":"product","link":"https:\/\/medsbase.com\/de\/product\/hgh-fragment-176-191\/","title":{"rendered":"HGH Fragment 176-191"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Kurze Antwort \u2014 Was ist HGH-Fragment 176-191?<\/h3>\n<p style=\"margin: 0;\"><strong>HGH Fragment 176-191<\/strong> ist ein synthetisches Peptid aus 16 Aminos\u00e4uren, das den C-terminalen Resten 176\u2013191 des <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">menschlichen Wachstumshormons<\/a>. In published studies it retains the lipolytic (fat-mobilising) and glucose-modulating activity of the parent HGH molecule but lacks GH-receptor binding affinity and therefore does not activate IGF-1 production, chondrocyte signalling, or any of the growth-promoting effects of full-length HGH. Sequence: YLRIVQCRSVEGSCGF. Supplied in 5\u201315\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Was Sie bei MedsBase erhalten:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/de\/reviews\/\">Kundenbewertungen<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Jede Bestellung ist durch unsere <a href=\"https:\/\/medsbase.com\/de\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> abgedeckt \u2014 wenn Ihr Paket nicht innerhalb von 20 Werktagen ankommt, versenden wir es erneut.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Spezifikation<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS-Nummer<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">66004-57-7 (HGH-Fragment 176-191; unterscheidet sich von AOD9604 CAS 221231-10-9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekularformel<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekulargewicht<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1817,06 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenz<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF, 16 Aminos\u00e4uren; Positionen 176\u2013191 des nativen menschlichen Wachstumshormons, beh\u00e4lt die Cys182\u2013Cys189-Disulfidbr\u00fccke des urspr\u00fcnglichen Molek\u00fcls bei)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Form<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilisat (wei\u00df bis leicht gelblich)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Reinheit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC-best\u00e4tigt, COA auf Anfrage)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Lagerung<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilisat: 2\u20138 \u00b0C (K\u00fchlschrank) f\u00fcr Arbeitsvorrat; \u221220 \u00b0C zur Langzeitlagerung unge\u00f6ffneter Fl\u00e4schchen. Rekonstituiert: 2\u20138 \u00b0C, innerhalb von ~30 Tagen verwenden. Vor Licht sch\u00fctzen. Die rekonstituierte L\u00f6sung nicht einfrieren und auftauen.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>L\u00f6slichkeit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakteriostatisches Wasser (empfohlen) oder steriles Wasser f\u00fcr k\u00fcrzere Anwendungszeitr\u00e4ume<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Was ist HGH-Fragment 176-191?<\/h2>\n<p><strong>HGH Fragment 176-191<\/strong> is a 16-amino-acid synthetic peptide corresponding to the C-terminal residues 176 through 191 of native human growth hormone. The fragment was identified through structure-function studies on HGH conducted at Monash University in the 1990s, when investigators systematically truncated and modified the HGH molecule to map the regions responsible for each of its multiple biological activities. The 176-191 region proved to retain the lipolytic (fat-mobilising) and antilipogenic activity of full-length HGH while completely losing the GH-receptor-binding domain that resides in the N-terminal portion of the parent molecule. The well-characterised sequence is YLRIVQCRSVEGSCGF with the native Cys182\u2013Cys189 intramolecular disulfide bridge preserved (these become Cys7\u2013Cys14 within the fragment numbering). Molecular weight 1817.06\u00a0Da, empirical formula C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. HGH-Fragment 176-191 ist strukturell und pharmakologisch <strong>unterschiedlich von AOD9604<\/strong> \u2014 an analog developed by Metabolic Pharmaceuticals that adds an N-terminal tyrosine substitution (creating Tyr-HGH 177-191) and modifies the disulfide bridge. AOD9604 has its own CAS (221231-10-9) and pharmacological profile and should not be confused with the unmodified 176-191 fragment supplied here. HGH Fragment 176-191 is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. The fragment is <strong>nicht zugelassen<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the full-length parent molecule, see our <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> Produktseite. <\/p>\n<h2>Wirkmechanismus \u2013 Lipolytische Aktivit\u00e4t ohne GH-Rezeptorbindung<\/h2>\n<p>Was HGH-Fragment 176-191 mechanistisch einzigartig macht, ist die <strong>Entkopplung der Lipolyse von der Wachstumsachsen-Signalgebung<\/strong> \u2014 one of the cleanest examples of structure-function dissection in peptide pharmacology studies:<\/p>\n<ul>\n<li><strong>Fehlende GH-Rezeptorbindung<\/strong> \u2014 Die GH-Rezeptor-Bindungsfl\u00e4che des nativen HGH befindet sich im N-terminalen Teil des Molek\u00fcls (Region der Reste 1\u2013120), nicht im C-terminalen Fragment 176\u2013191. Folglich bindet HGH-Fragment 176-191 NICHT an den Wachstumshormonrezeptor (GHR), aktiviert NICHT die JAK2\/STAT5-Signalgebung, induziert NICHT die hepatische IGF-1-Produktion und bewirkt NICHT die wachstumsf\u00f6rdernden, chondrozytenstimulierenden oder insulin-gegenregulatorischen Effekte des Elternmolek\u00fcls. <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> molecule. This is the defining negative pharmacological property and the basis for its studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>Erhaltene lipolytische Aktivit\u00e4t<\/strong> \u2014 Published studies has documented that HGH Fragment 176-191 retains the fat-mobilising activity of full HGH at adipocytes. The exact molecular target underlying the lipolytic effect remains an active studies question; proposed mechanisms include direct action on adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase, and altered fatty-acid oxidation kinetics. The lipolytic signal is preferentially observed in visceral adipose tissue depots in some published rodent studies, paralleling but mechanistically distinct from the <a href=\"https:\/\/medsbase.com\/de\/tesamorelin\/\">Tesamorelin<\/a> visceral-adiposity signal.<\/li>\n<li><strong>Antilipogene Aktivit\u00e4t<\/strong> \u2014 In addition to stimulating fat mobilisation, HGH Fragment 176-191 suppresses lipogenic gene expression in adipocyte study models \u2014 reducing the rate of new fat storage in parallel with increasing fat mobilisation. The two effects produce a net negative-fat-balance signal in adipose tissue.<\/li>\n<\/ul>\n<p>The structure-function-decoupling property is the principal scientific reason HGH Fragment 176-191 has remained in active studies despite never reaching regulatory approval as a stand-alone therapeutic. It is a useful tool for users who want to study HGH&#8217;s lipolytic effects independently from its growth-promoting effects \u2014 a separation that is impossible to achieve with full-length HGH or with GH secretagogues that drive endogenous full-length GH release. Plasma half-life is short (~30 minutes); subcutaneous administration is the standard administration route. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HGH Fragment 176-191 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Pharmakologie der Adipozytenlipolyse<\/strong> \u2014 isolierte Charakterisierung des lipolytischen Mechanismus, Studien zur Interaktion mit Beta-3-adrenergen Rezeptoren, Aktivierung der hormonsensitiven Lipase, Kinetik der Fetts\u00e4uremobilisation<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), regional adipose-tissue depot effects (visceral vs subcutaneous), lipolysis-without-growth-axis-confound studies designs<\/li>\n<li><strong>HGH structure-function studies<\/strong> \u2014 mechanistische Aufschl\u00fcsselung der wachstumsf\u00f6rdernden vs lipolytischen Aktivit\u00e4tsdom\u00e4nen innerhalb des nativen HGH; HGH Fragment 176-191 als das kanonische \u201cnur Lipolyse\u201d-Werkzeug, mit <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> als dem Vollaktivit\u00e4ts-Vergleich<\/li>\n<li><strong>Lipogenic gene-expression studies<\/strong> \u2014 Adipozyten-Differenzierung, Lipid-Tropfen-Bildung, PPAR\u03b3- und SREBP-1-Signalweg-Interaktionen<\/li>\n<li><strong>Visceral adiposity studies<\/strong> \u2014 direkte Vergleichsstudien mit <a href=\"https:\/\/medsbase.com\/de\/tesamorelin\/\">Tesamorelin<\/a> as the GHRH-axis visceral-fat-reducing tool; published interest in dissecting GH-receptor-dependent vs GH-receptor-independent visceral-fat-loss mechanisms<\/li>\n<li><strong>Glucose homeostasis studies<\/strong> \u2014 unlike full-length HGH, HGH Fragment 176-191 does not produce the insulin-counter-regulatory effects observed with parent HGH; published studies uses this difference to dissect direct GH glycaemic effects<\/li>\n<li><strong>Comparative HGH-axis studies<\/strong> \u2014 Benchmarking gegen <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> (vollst\u00e4ndiges Ausgangshormon), <a href=\"https:\/\/medsbase.com\/de\/tesamorelin\/\">Tesamorelin<\/a> (viszerales-Fett-GHRH-Analogon), und <a href=\"https:\/\/medsbase.com\/de\/sermorelin\/\">Sermorelin<\/a> \/ <a href=\"https:\/\/medsbase.com\/de\/cjc-1295-with-dac\/\">CJC-1295<\/a> (GHRH-Achsen-Stimulatoren).<\/li>\n<\/ul>\n<p>For broader context on where HGH Fragment 176-191 fits within the growth-axis and adipose-tissue studies landscape, see <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> als das vollst\u00e4ndige Elternpeptid, <a href=\"https:\/\/medsbase.com\/de\/tesamorelin\/\">Tesamorelin<\/a> f\u00fcr den GHRH-Achsen-Ansatz zur viszeralen Adipositas, und <a href=\"https:\/\/medsbase.com\/de\/sermorelin\/\">Sermorelin<\/a> + <a href=\"https:\/\/medsbase.com\/de\/cjc-1295-with-dac\/\">CJC-1295 mit DAC<\/a> for endogenous GH-pulse support. Browse the full <a href=\"https:\/\/medsbase.com\/de\/peptides\/\">Peptid-Katalog<\/a> f\u00fcr verwandte Verbindungen. <\/p>\n<h2>Verf\u00fcgbare St\u00e4rken und Konzentrationen<\/h2>\n<p>MedsBase stocks HGH Fragment 176-191 in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Vial-St\u00e4rke<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typischer Anwendungsfall<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Packungsgr\u00f6\u00dfen<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short protocols, pilot dosing, single-cohort lipolysis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, multi-week protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protokolle mit verl\u00e4ngertem Zyklus, niedrigste Kosten pro mg, Multikohortenstudien<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. <\/p>\n<h2>Vergleich \u2014 HGH Fragment 176-191 vs HGH 191AA<\/h2>\n<p>HGH Fragment 176-191 und <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> are a structure-function decoupled pair \u2014 the fragment is literally a piece of the full-length parent. Comparing them isolates the GH-receptor-binding activity (present in full-length, absent in fragment) from the lipolytic activity (present in both). The comparison is one of the cleanest mechanistic dissections available in current growth-axis studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kriterium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH Fragment 176-191<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH 191AA (vollst\u00e4ndig)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>L\u00e4nge<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16 Aminos\u00e4uren (~1,8 kDa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">191 Aminos\u00e4uren (~22 kDa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>GH-Rezeptorbindung<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nein (Bindungsdom\u00e4ne ist N-terminal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ja (vollst\u00e4ndiges Molek\u00fcl)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>IGF-1-Induktion<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Keine<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Erhebliche hepatische Induktion<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Lipolytische Aktivit\u00e4t<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ja (erhalten)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ja (vollst\u00e4ndige Elternmolek\u00fcl-Aktivit\u00e4t)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Wachstumsf\u00f6rdernde Effekte<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Keine<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Erheblich (kanonisches anaboles Peptid)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Insulin-gegenregulatorischer Effekt<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nein<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ja (vor\u00fcbergehende Insulinresistenz)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Plasmahalbwertszeit<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30 Minuten<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3\u20135 Stunden<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Klinisch zugelassene Anwendung<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Keine<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mehrere Indikationen (Genotropin, Humatrope etc.)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typische Dosis<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">200\u2013500 \u00b5g, 1\u20133x t\u00e4glich<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20138 IE pro Verabreichung<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in isolated lipolysis pharmacology without the confound of GH-receptor-driven growth and metabolic effects, HGH Fragment 176-191 is the canonical &#8220;lipolysis-only&#8221; tool. For studies investigating the full GH\/IGF axis or comparing with secretagogue-driven endogenous GH release, <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> is the appropriate full-length reference. Many published studies designs use both in parallel arms to dissect which HGH effects depend on GH-receptor signalling vs which arise from the C-terminal lipolytic mechanism. <\/p>\n<h2>Lagerung und Rekonstitution<\/h2>\n<p><strong>Vor der Rekonstitution:<\/strong> Lagern Sie lyophilisierte Fl\u00e4schchen gek\u00fchlt bei 2\u20138 \u00b0C in der Originalverpackung als kurzfristigen Arbeitsvorrat. F\u00fcr unge\u00f6ffnete Langzeitlagerung einfrieren bei \u221220 \u00b0C. Lyophilisiertes HGH-Fragment 176-191 ist unter K\u00fchlung bis zu 24 Monate und bei \u221220 \u00b0C bis zu 36 Monate stabil. Vermeiden Sie Gefrier-Tau-Zyklen des lyophilisierten Pulvers. Wie bei anderen Disulfid-verbr\u00fcckten Peptiden h\u00e4ngt die Fragmentaktivit\u00e4t von der intakten Cys182\u2013Cys189-Bindung ab (Cys7\u2013Cys14 nach Fragmentnummerierung) \u2013 eine Handhabung, die das Disulfid st\u00f6rt, beeintr\u00e4chtigt die Aktivit\u00e4t. <strong>Rekonstitutionsverfahren:<\/strong> Injizieren Sie bakterostatisches Wasser an der Seitenwand des Peptidfl\u00e4schchens entlang (nicht direkt auf den lyophilisierten Kuchen). F\u00fcr ein 5 mg-Fl\u00e4schchen ergibt 2,0 mL bakterostatisches Wasser eine Arbeitskonzentration von 2,5 mg\/mL \u2013 0,04 mL liefern 100 mcg; 0,1 mL liefern 250 mcg; 0,2 mL liefern 500 mcg. Sanft schwenken \u2013 nicht <strong>nicht<\/strong> Sch\u00fctteln Sie \u2014 und lassen Sie 2\u20135 Minuten f\u00fcr die vollst\u00e4ndige Aufl\u00f6sung. Eine korrekt rekonstituierte L\u00f6sung sollte klar und farblos sein. <strong>gek\u00fchlt bei 2\u20138 \u00b0C lagern und innerhalb von 30 Tagen verwenden. Rekonstituierte L\u00f6sung nicht einfrieren.<\/strong> Lagern Sie gek\u00fchlt bei 2\u20138 \u00b0C und verwenden Sie innerhalb von 30 Tagen f\u00fcr optimale Stabilit\u00e4t. Frieren Sie die rekonstituierte L\u00f6sung nicht ein \u2013 Gefrier-Tau-Zyklen beeintr\u00e4chtigen die Peptidintegrit\u00e4t und k\u00f6nnen die Disulfidbindung st\u00f6ren. Verwerfen Sie jedes Fl\u00e4schchen mit Tr\u00fcbung, Ausf\u00e4llung oder Verf\u00e4rbung. <\/p>\n<h2 id=\"faqs\">H\u00e4ufig gestellte Fragen<\/h2>\n<h3>What is HGH Fragment 176-191 used for in studies?<\/h3>\n<p>HGH Fragment 176-191 is used in studies investigating isolated adipocyte lipolysis pharmacology, obesity and body-composition regulation without growth-axis confound, HGH structure-function dissection, lipogenic gene-expression regulation, regional adipose-tissue depot effects, and comparative GH-axis vs lipolysis-only studies designs. It is the canonical &#8220;lipolysis-only&#8221; peptide derived from native HGH. The pharmaceutical-grade HGH Fragment 176-191 sold here is <strong>nicht<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Wie unterscheidet sich HGH-Fragment 176-191 von HGH 191AA?<\/h3>\n<p>HGH-Fragment 176-191 besteht aus nur 16 Aminos\u00e4uren \u2013 dem C-terminalen St\u00fcck des vollst\u00e4ndigen 191-Aminos\u00e4uren-HGH. Dem Fragment fehlt die GH-Rezeptor-Bindungsdom\u00e4ne (die im N-terminalen Teil des Elternmolek\u00fcls liegt), daher bindet es NICHT an GHR, induziert NICHT IGF-1 und zeigt KEINE der wachstumsf\u00f6rdernden oder insulin-gegenregulatorischen Effekte von vollem HGH. Es beh\u00e4lt nur die lipolytische und antilipogene Aktivit\u00e4t. <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> ist das vollst\u00e4ndige Elternmolek\u00fcl mit sowohl lipolytischer ALS AUCH Wachstumsachsen-Aktivit\u00e4t. <\/p>\n<h3>Wie unterscheidet sich HGH-Fragment 176-191 von AOD9604?<\/h3>\n<p>Es handelt sich <strong>um unterschiedliche Verbindungen<\/strong> that are frequently confused. HGH Fragment 176-191 (CAS 66004-57-7) is the unmodified C-terminal fragment of native HGH. AOD9604 (CAS 221231-10-9) is a modified analog developed by Metabolic Pharmaceuticals \u2014 specifically, AOD9604 adds an N-terminal tyrosine substitution producing Tyr-HGH 177-191, with engineered changes to the disulfide bridge for improved stability and oral bioavailability studies. The two have related but distinct pharmacology. This product is the unmodified 176-191 fragment, not AOD9604. <\/p>\n<h3>What is the typical HGH Fragment 176-191 dose?<\/h3>\n<p>Published preclinical protocols typically use 200\u2013500\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 4\u201312 week cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.2\u00a0mL equals 500\u00a0mcg. <\/p>\n<h3>Ist HGH-Fragment 176-191 von der FDA zugelassen?<\/h3>\n<p>No. HGH Fragment 176-191 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The related compound AOD9604 was investigated in clinical trials for obesity but did not achieve regulatory approval. <\/p>\n<h3>Wie sollte HGH-Fragment 176-191 gelagert werden?<\/h3>\n<p>Lyophilisierte Flaschen: gek\u00fchlt bei 2\u20138 \u00b0C f\u00fcr kurzfristige Arbeitsbest\u00e4nde oder bei \u221220 \u00b0C f\u00fcr die Langzeitlagerung unge\u00f6ffneter Flaschen. Rekonstituierte L\u00f6sung: gek\u00fchlt bei 2\u20138 \u00b0C, innerhalb von 30 Tagen verwenden. Rekonstituierte L\u00f6sung nicht einfrieren \u2013 Gefrier-Tau-Zyklen degradieren das Peptid und k\u00f6nnen die essentielle Cys182\u2013Cys189-Disulfidbr\u00fccke st\u00f6ren. Immer vor direktem Licht sch\u00fctzen. <\/p>\n<h3>Wie rekonstituiere ich HGH-Fragment 176-191?<\/h3>\n<p>Befolgen Sie das oben beschriebene Rekonstitutionsverfahren. Geben Sie bakterienstatisches Wasser an der Seitenwand des Fl\u00e4schchens hinzu (nicht auf den lyophilisierten Kuchen), schwenken Sie vorsichtig und lassen Sie 2\u20135 Minuten zur vollst\u00e4ndigen Aufl\u00f6sung. Sch\u00fctteln Sie <strong>nicht<\/strong> Sch\u00fctteln Sie die Flasche nicht \u2013 starke Bewegung kann die Disulfidbindung st\u00f6ren. Eine korrekt rekonstituierte L\u00f6sung ist klar und farblos. F\u00fcr eine 5 mg-Flasche + 2,0 mL L\u00f6sungsmittel betr\u00e4gt die Arbeitskonzentration 2,5 mg\/mL. <\/p>\n<h3>Welche St\u00e4rken f\u00fchrt MedsBase?<\/h3>\n<p>MedsBase carries HGH Fragment 176-191 in 5\u00a0mg, 10\u00a0mg, and 15\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Warum beeinflusst HGH-Fragment 176-191 nicht IGF-1?<\/h3>\n<p>The GH-receptor-binding surface of native human growth hormone is located in the N-terminal portion of the 191-amino-acid molecule, not in the C-terminal 176\u2013191 region. Because the fragment lacks the receptor-binding domain, it cannot activate the GH receptor; without GHR activation, the downstream JAK2\/STAT5 signalling cascade that drives hepatic IGF-1 transcription is not engaged. This structural-functional decoupling is the principal scientific reason the fragment retains studies interest as a lipolysis-isolating tool. <\/p>\n<h3>Woher kommt die lipolytische Aktivit\u00e4t, wenn nicht von der GH-Rezeptor-Bindung?<\/h3>\n<p>The exact molecular target of HGH Fragment 176-191&#8217;s lipolytic action remains an active studies question. Proposed mechanisms include direct interaction with adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase activity, and altered fatty-acid oxidation kinetics in adipose tissue. The fragment also suppresses lipogenic gene expression, suggesting it acts on multiple adipocyte-specific pathways simultaneously. Published studies continues to characterise the exact receptor or binding-site target. <\/p>\n<h3>Does HGH Fragment 176-191 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented a notably clean safety profile at typical doses, with the main on-target effect being lipolysis. The absence of GH-receptor binding means none of the GH-axis side effects observed with full-length HGH (transient insulin resistance, joint discomfort, sodium retention, mitogenic signalling) are present. Long-term human safety data is limited because the unmodified fragment has not undergone modern regulatory review (though the related AOD9604 has been investigated more extensively in clinical trials). <\/p>\n<h3>Was ist die Halbwertszeit von HGH-Fragment 176-191?<\/h3>\n<p>In preclinical studies, HGH Fragment 176-191 has a plasma half-life of approximately 30 minutes following subcutaneous administration \u2014 shorter than full-length HGH (~3\u20135 hours) due to the smaller molecular size and absence of albumin-binding modifications. The short half-life means typical protocols use multiple daily administrations or continuous-release formulations for sustained-exposure work. <\/p>\n<h3>How long does HGH Fragment 176-191 take to show effects in preclinical studies?<\/h3>\n<p>Acute effects on adipocyte lipolysis and fatty-acid mobilisation are detectable within hours of administration. Body-composition effects in DIO rodent models typically become statistically significant after 2\u20134 weeks of regular dosing and continue to accrue through 8\u201312 weeks of continuous administration. The kinetics are similar to other adipose-tissue-targeted compounds. <\/p>\n<h3>Kann ich HGH-Fragment 176-191 f\u00fcr den internationalen Versand bestellen?<\/h3>\n<p>Ja. MedsBase versendet HGH-Fragment 176-191 weltweit \u00fcber unser dediziertes Peptid-Versandnetzwerk. Bestellungen, die nur Peptide enthalten, qualifizieren sich f\u00fcr unseren eigenst\u00e4ndigen Peptid-Versandservice. Alle Bestellungen werden in temperaturkontrollierter Verpackung mit vollst\u00e4ndiger Nachverfolgung versendet und sind durch unsere <a href=\"https:\/\/medsbase.com\/de\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Adipose, Growth-Axis, and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/de\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Vollst\u00e4ndiges rekombinantes menschliches Wachstumshormon \u2014 das Elternmolek\u00fcl dieses Fragments<\/li>\n<li><a href=\"\/de\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose-tissue studies; FDA-approved for HIV-associated lipodystrophy<\/li>\n<li><a href=\"\/de\/cjc-1295-with-dac\/\"><strong>CJC-1295 mit DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 endogenous GH-pulse support<\/li>\n<li><a href=\"\/de\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 short-acting GHRH use<\/li>\n<li><a href=\"\/de\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Selective growth hormone secretagogue \u2014 clean GH pulse studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Weiterf\u00fchrende Literatur<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the HGH-axis studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Durchst\u00f6bern Sie das gesamte Sortiment <a href=\"https:\/\/medsbase.com\/de\/peptides\/\"><strong>Peptid-Katalog<\/strong><\/a>, mit verwandten Wachstumsachsen-Verbindungen wie <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> (vollst\u00e4ndiges Ausgangshormon), <a href=\"https:\/\/medsbase.com\/de\/tesamorelin\/\">Tesamorelin<\/a> (viszerale Adipositas GHRH-Analogon), <a href=\"https:\/\/medsbase.com\/de\/sermorelin\/\">Sermorelin<\/a> und <a href=\"https:\/\/medsbase.com\/de\/cjc-1295-with-dac\/\">CJC-1295 mit DAC<\/a> for endogenous-pulse studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 16-aa C-terminales Fragment des menschlichen Wachstumshormons<br \/>\n\u2705 Beh\u00e4lt lipolytische Aktivit\u00e4t bei, keine GH-Rezeptorbindung<br \/>\n\u2705 Keine IGF-1-Induktion oder wachstumsf\u00f6rdernde Effekte<br \/>\n\u2705 Lipolysis-only tool (distinct from AOD9604)<br \/>\n\u2705 \u226599% HPLC-Reinheit, COA auf Anfrage<\/p>\n<p><strong>HGH Fragment 176-191<\/strong> enth\u00e4lt synthetische Peptidverbindung.<\/p>","protected":false},"featured_media":70959,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6288,6289,5441],"class_list":["post-70781","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-hgh","product_tag-hgh-fragment","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product\/70781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/comments?post=70781"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media\/70959"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media?parent=70781"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_brand?post=70781"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_cat?post=70781"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_tag?post=70781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}